1. Scrip
  2. >>Business
  3. >>Deals

NewAmsterdam Is Behind Another Try At CETP Inhibition, With Menarini’s Help

 
• By Joseph Haas

Years after failures by Merck, Lilly, Pfizer and Roche, NewAmsterdam hopes to bring a CETP inhibitor to market to lower cholesterol, and signs on with Menarini to lead commercial efforts in Europe.

cholesterol _181632251_1200.jpg
NewAmsterdam hopes to succeed where other firms failed in battling cholsterol

Some of the biggest names in biopharma took their best shot at cholesteryl ethyl transfer protein (CETP) inhibition to reduce LDL cholesterol and the risk of cardiovascular disease a decade ago or more, but privately held NewAmsterdam Pharma BV thinks it can get to the finish line with a candidate licensed from Amgen, Inc. On 28 June, the biotech got €142.5m (about $151m) up front from Menarini Group in exchange for EU commercial rights to the Phase III CETP inhibitor obicetrapib.

When Merck & Co., Inc. ended development of its CETP inhibitor, anacetrapib, despite success in a 30,000-plus patient cardiovascular outcomes trial in 2017, many industry observers thought that would be the final blow for the class after high-profile and expensive failures at Pfizer Inc., Roche Holding AG and Eli Lilly and Company. (Also see "Merck, Lilly Vow To Press On With CETP, Despite Dalcetrapib Disaster" - Pink Sheet, 7 May, 2012

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

More from Business

Gilead Joins Pharma’s US Investment Rush

 
• By Alaric DeArment

The company drew praise from the Trump administration as one of multiple companies announcing multibillion-dollar investments in US manufacturing and R&D.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

HAYA Raises $65m To Take First Long Non-Coding RNA Program Into The Clinic

 
• By Mandy Jackson

HTX-001 targeting the long non-coding RNA known as Wisper is being developed for non-obstructive hypertrophic cardiomyopathy. HAYA partnered with Lilly last year in obesity.